journal article·2026-05

A Structurally Stabilized Lipopolymer Nanoplatform Targeting Pan‐Tissue Antigen‐Presenting Cells Enables Durable in situ mRNA Cancer Immunotherapy

Ling Zeng, Qian Shen, Lingyu Wei, Meng Jiang, Jing Liao, Yupeng Ren, Zixi Zhang, Hui Fan, Xinxiu Cao, Jinjin Chen, Jianxun Ding, Xuesi Chen

Advanced Materials· Volume 38· Issue 30
Publisher page

Abstract

ABSTRACT Messenger RNA (mRNA) vaccines have transformed cancer immunotherapy, yet delayed immune activation, multi‐dose requirements, and poor efficacy in immunosuppressive tumor microenvironments (TMEs) hinder current platforms. Here, a structurally stabilized lipopolymer nanoparticle (LPNP) platform is proposed for in situ mRNA vaccination targeting antigen‐presenting cells (APCs). Central to this system is a rationally engineered double‐branched lipopolymer, P6CIT, whose unique molecular architecture enhances hydrophobic microviscosity and intermolecular packing, increasing particle rigidity and preventing premature disassembly in biological fluids. This stabilization enhances circulation stability and promotes favorable biodistribution to tumor sites and lymphoid organs, resulting in a 6.9‐fold increase in the spleen and a 13.6‐fold increase in lymph nodes, key sites for adaptive immune activation. Upon intratumoral administration, the LPNP co‐delivers mRNAs encoding tumor antigens and IL‐12, synergistically reprogramming the TMEs and amplifying APC‐mediated T cell priming. In situ vaccination achieves a 42% complete response in a B16‐OVA melanoma model and outperforms ALC‐0315 LNPs in wild‐type B16F10 tumors. This work highlights chemical‐level structural optimization enabling potent, simplified mRNA immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Medical Research Center Guangzhou Key Laboratory of Medical Nanomaterials Sun Yat‐Sen Memorial Hospital Sun Yat‐Sen University Guangzhou P. R. China

Department of Pharmacy the Second Affiliated Hospital Hengyang P. R. China

School of Materials Science and Engineering Hunan University of Science and Technology Hengyang P. R. China

State Key Laboratory of Polymer Science and Technology Changchun Institute of Applied Chemistry Chinese Academy of Sciences Changchun P. R. China

Funding

National Natural Science Foundation of China · Science and Technology Planning Project of Guangdong Province

References (29)

Show source-provided references
1. 10.1021/acsnano.2c1258410.1021/acsnano.2c12584 ↗
2. 10.1146/annurev‐bioeng‐110220‐03172210.1146/annurev‐bioeng‐110220‐031722 ↗
3. 10.1016/j.cclet.2022.10809810.1016/j.cclet.2022.108098 ↗
4. 10.1021/polymscitech.5c0001010.1021/polymscitech.5c00010 ↗
5. 10.1038/s41571‐024‐00902‐110.1038/s41571‐024‐00902‐1 ↗
6. 10.1016/s0140‐6736(23)02268‐710.1016/s0140‐6736(23)02268‐7 ↗
7. 10.1056/NEJMoa202248310.1056/NEJMoa2022483 ↗
8. 10.1038/ni.312310.1038/ni.3123 ↗
9. 10.1146/annurev‐cancerbio‐060820‐11170110.1146/annurev‐cancerbio‐060820‐111701 ↗
10. 10.1038/s43018‐022‐00352‐710.1038/s43018‐022‐00352‐7 ↗
11. 10.1016/j.cclet.2024.11006710.1016/j.cclet.2024.110067 ↗
12. 10.1038/s41586‐020‐2537‐910.1038/s41586‐020‐2537‐9 ↗
13. 10.1038/s41422‐024‐00990‐910.1038/s41422‐024‐00990‐9 ↗
14. 10.1038/s41571‐022‐00600‐w10.1038/s41571‐022‐00600‐w ↗
15. 10.1007/s10118‐025‐3397‐410.1007/s10118‐025‐3397‐4 ↗
16. 10.1021/polymscitech.5c0011010.1021/polymscitech.5c00110 ↗
17. 10.1038/s41573‐024‐00974‐910.1038/s41573‐024‐00974‐9 ↗
18. 10.1021/acs.molpharmaceut.2c0102410.1021/acs.molpharmaceut.2c01024 ↗
19. 10.1016/j.apsb.2024.12.03010.1016/j.apsb.2024.12.030 ↗
20. 10.1126/sciadv.abo182710.1126/sciadv.abo1827 ↗
21. 10.1073/pnas.220784111910.1073/pnas.2207841119 ↗
22. 10.1016/j.immuni.2013.07.01110.1016/j.immuni.2013.07.011 ↗
23. 10.1038/s41541‐023‐00751‐610.1038/s41541‐023‐00751‐6 ↗
24. 10.1016/j.ejpb.2024.11422210.1016/j.ejpb.2024.114222 ↗
25. 10.1073/pnas.210925611810.1073/pnas.2109256118 ↗
26. 10.1002/smsc.20220007110.1002/smsc.202200071 ↗
27. 10.1002/cbic.20190051010.1002/cbic.201900510 ↗
28. 10.1038/cdd.2014.13410.1038/cdd.2014.134 ↗
29. 10.1016/j.cell.2025.11.02310.1016/j.cell.2025.11.023 ↗